Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meclizine
Drug ID BADD_D01361
Description Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects.[L6760] Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.
Indications and Usage Indicated for the symptomatic treatment of nausea, vomiting, and dizziness associated with motion sickness,[L6772] and management of vertigo due to various causes, including radiation sickness, Meniere’s syndrome, labyrinthitis and other vestibular disturbances.[L6766]
Marketing Status approved
ATC Code R06AE05
DrugBank ID DB00737
KEGG ID D08163
MeSH ID D008468
PubChem ID 4034
TTD Drug ID D0T1XW
NDC Product Code 71554-010; 51927-0043; 50268-522; 71335-0732; 0904-6516; 65162-441; 0615-8303; 70518-1402; 67763-116
UNII 3L5TQ84570
Synonyms Meclizine | Parachloramine | Meclozine | Antivert | Bonamine | Bonine | Chiclida | Histametizyn | Meclizine Hydrochloride | Hydrochloride, Meclizine | Meclizine Dihydrochloride | Dihydrochloride, Meclizine | Meclizine Monohydrochloride | Monohydrochloride, Meclizine | Ru-Vert-M | Ru Vert M | Agyrax | D-Vert | D Vert | DVert
Chemical Information
Molecular Formula C25H27ClN2
CAS Registry Number 569-65-3
SMILES CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Asthenia08.01.01.001---
Completed suicide08.04.01.010; 19.12.01.0010.000060%-
Depression19.15.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.000511%
Drug hypersensitivity10.01.01.0010.000511%-
Drug ineffective08.06.01.0060.001112%-
Dry mouth07.06.01.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Feeling hot08.01.09.009---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Headache17.14.01.001--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Oedema08.01.07.006; 14.05.06.010---
Oligohydramnios18.05.01.0010.000060%-
Paraesthesia17.02.06.005; 23.03.03.094--
Periorbital oedema06.08.03.017; 10.01.05.010; 23.04.01.002--
Petechiae01.01.03.002; 23.06.01.003; 24.07.06.004---
Pruritus23.03.12.001--
Rash23.03.13.001---
Rash erythematous23.03.13.029---
Rash maculo-papular23.03.13.004--
Somnolence17.02.04.006; 19.02.05.003--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.0020.000204%
Vision blurred06.02.06.007; 17.17.01.010--
The 1th Page    1 2    Next   Last    Total 2 Pages